Introduction {#s001}
============

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world, accounting for 70%--85% of primary liver cancer.^[@B1],[@B2]^ As a fatal malignant tumor of the liver, HCC is the third leading cause of cancer-related death worldwide.^[@B3]^ In clinical practice, the treatment of HCC mainly relies on surgical resection, especially for patients at an early stage.^[@B4]^ Since more than half of HCC patients are diagnosed at an advanced stage,^[@B5]^ adjuvant therapeutic strategies, including chemotherapy and radiotherapy, provide great therapeutic potential for HCC.^[@B6]^ However, the prognosis of HCC patients remains poor due to tumor metastasis and recurrence, as well as drug resistance and low therapeutic specificity. Therefore, research into novel therapeutic strategies for HCC is urgently needed.

Due to the adverse effects of and drug resistance to conventional antitumor drugs, natural bioactive substances emerge as potential sources of antitumor drugs with low toxicity.^[@B7]^ Laminarin (1--3,1-6-glucan) is a polysaccharide in seaweed (*Laminaria japonica*) that is composed of 1,3- and 1,6-glycosidic bond-linked β-D-glucopyranose molecules. Laminarin exhibits bioactivities similar to those of β-glucan, such as immune-enhancing, antioxidant, anti-aging, and antitumor properties.^[@B8]^ Until now, the antitumor roles of laminarin have mainly been identified in colorectal carcinoma (CC). For example, laminarin induces the apoptosis of LOVO human colon cancer cells through a mitochondrial pathway.^[@B9]^ Laminarin induces the apoptosis of HT-29 cells and increases the percentage of cells in the sub-G1 and G2/M phases.^[@B10]^ Laminarin inhibits the colony formation of CC DLD-1 cells and increases the 1,6-linked glucose residue content to enhance the antitumor effect.^[@B11]^ However, related studies on the specific roles of laminarin in HCC are still limited.

Senescence marker protein-30 (SMP-30) is a 34 kDa cytosolic marker of aging that decreases with age.^[@B12]^ SMP-30 is also known as regucalcin, which acts to protect cells from apoptosis by enhancing plasma membrane Ca(2+) pump activity.^[@B13]^ Moreover, SMP-30 serves as a prognostic marker and a potential therapeutic target for HCC.^[@B14],[@B15]^ It has been reported that SMP-30 expression is significantly reduced in HCC tissues compared with in adjacent non-tumor tissues and is negatively associated with the tumor size, TNM stage, and poor survival of HCC patients.^[@B14]^ Silencing of SMP-30 promotes the proliferation and invasion of HepG2 cells.^[@B15]^

Based on the antiaging effect of laminarin, we speculated that laminarin may upregulate SMP-30 expression. However, whether the regulatory roles of laminarin in HCC are related to SMP-30 is still unclear. In this study, the specific effects of laminarin on the proliferation and apoptosis of Bel-7404 and HepG2 cells and on the tumor growth in Hepa 1--6 tumor-bearing mice were evaluated. Our findings may reveal the antitumor effects of laminarin on HCC both *in vitro* and *in vivo* to provide a novel agent for the treatment of HCC.

Materials and Methods {#s002}
=====================

Cell culture {#s003}
------------

Human HCC cell lines Bel-7404 and HepG2, mouse HCC cell line Hepa 1--6, and normal liver cell line LO2 were purchased from the Cell Bank of Chinese Academy of Medical Sciences (Beijing, China). Cells were maintained in Dulbecco\'s modified Eagle\'s medium (DMEM) (HyClone, Los Angeles, CA) containing 10% fetal bovine serum (FBS) (Dojindo, Tokyo, Japan), 100 U/mL penicillin, and 100 μg/mL streptomycin. The cells were cultured in an incubator at 37°C with 5% CO~2~ and 95% humidity. Cells in the logarithmic growth phase were used for further assays.

Cell treatments {#s004}
---------------

Laminarin was purchased from Shanghai Jinsui Bio-Technology Co., Ltd. (Shanghai, China). Bel-7404 and HepG2 cells were seeded in 96-well plates at a density of 5 × 10^3^ cells/well. After 24 h of culturing, cells were incubated with DMEM containing different concentrations of laminarin (5, 15, 25, 35, and 45 mg/mL). DMEM containing 0 mg/mL laminarin was used as the control.

WST-8 cell proliferation assay {#s005}
------------------------------

Cell viability was detected in Bel-7404 and HepG2 cells at 24, 48, and 72 h post-treatment by using the CCK-8 Assay Kit (Dojindo) in accordance with the manufacturer\'s instructions. Simply, cells were seeded in 96-well plates at a density of 2 × 10^3^ cells/well and incubated with CCK-8 solution for 2 h at 37°C. The optical density (OD) at 450 nm was detected by a microplate reader (Synergy H1; Biotek, Winooski, VT).

Cell apoptosis assay {#s006}
--------------------

The apoptosis of Bel-7404 and HepG2 cells was detected by flow cytometry at 48 h post-treatment. Simply, cells were seeded in 96-well plates at a density of 4 × 10^5^ cells/well, and they were then incubated with annexin V-fluorescein isothiocyanate (Keygen, Nanjing, China) and propidium iodide for 10 min at 25°C in the dark. The apoptosis rate was analyzed on a flow cytometer (BD, Franklin Lakes, NJ).

Establishment of a tumor model in mice {#s007}
--------------------------------------

C57BL/6 mice that were 4--6 weeks old and 20 ± 2 g in weight were purchased from Beijing Huafukang Biotechnology Co., Ltd. (Beijing, China). Mice were fed in a specific pathogen-free animal room at 22°C--25°C with free access to water and food. Hepa 1--6 cells (1 × 10^7^) were subcutaneously injected into mice at the anterior right subaxillary (*N* = 24). When the tumors grew to a volume of 200 mm^3^, mice were injected with different concentrations of laminarin (400, 800, and 1200 mg/kg·d) through the caudal vein. Mice injected with an equal volume of physiological saline were considered as the control (0 mg/kg·d). The tumor volume was measured every 5 d, and the tumor weight was measured at 30 d post-injection. The inhibition rate was calculated as (1 - tumor weight-experimental group/tumor weight-control group) × 100%. All animal experiments were performed in accordance with the guidelines of the Public Health Service Policy on the Care and Use of Laboratory Animals.

Quantitative real-time PCR {#s008}
--------------------------

Total RNA was extracted from cells by using an RNA extraction kit (TaKaRa, Dalian, China) and reverse-transcribed by using a cDNA synthesis kit (TaKaRa) in accordance with the manufacturer\'s instructions. Quantitative real-time PCR (qPCR) was performed on a LightCycler PCR instrument (Roche, Basel, Switzerland) by using the TB Green RT-PCR kit with specific primers (SMP-30-F, 5′-GCAACCTGAAGCTGGTGGAA-3′; SMP-30-R, 5′-GACCTGTCCTCATCCCGCATA-3′). GAPDH was used as an internal control (GAPDH-F, 5′-CCATCTACGAGGGCTACGC-3′; GAPDH-R, 5′-GGAAGGAGGGCTGGAACA-3′). The PCR protocol included 95°C for 10 min, 40 cycles of 95°C for 5 s and 60°C for 30 s, and a final extension at 72°C for 3 min. Relative expression of SMP-30 was calculated with the 2^−ΔΔCt^ method.

Western blot analysis {#s009}
---------------------

Total proteins were isolated from cells by using a total protein extraction kit (Vazyme, Nanjing, China), and they were quantified by using a BCA protein assay kit (Vazyme). The proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene fluoride membrane (BD). The membrane was blocked with 5% skim milk for 3 h and incubated with specific primary antibodies, including anti-SMP-30 (1:200; Abcam, Cambridge, England) and anti-β-actin (1:5000; Fdbio, Hangzhou, China) overnight at 4°C. Then, the membrane was incubated with horseradish peroxidase-conjugated secondary antibody (1:5000; Fdbio) for 2 h at 25°C. The protein bands were visualized by using an enhanced chemiluminescence kit (Fdbio) and quantified by using a gel imaging analysis system (Olympus, Tokyo, Japan).

Statistical analysis {#s010}
--------------------

Statistical analysis was performed by using SPSS version 13.0 (SPSS, Inc., Chicago, IL). Experiments were performed at least in triplicate, and the data were expressed as the mean ± standard deviation. Comparison between different groups was determined by *t*-test for two groups and one-way ANOVA for more than two groups. A *p*-value less than 0.05 was considered statistically significant.

Results {#s011}
=======

Laminarin inhibited the proliferation of HCC cells {#s012}
--------------------------------------------------

The viability (OD at 450 nm) of Bel-7404 and HepG2 cells was detected by WST-8 cell proliferation assay. As shown in [Figure 1](#f1){ref-type="fig"}, the treatment with laminarin (48 h) significantly decreased the viability of Bel-7404 cells in a dose-dependent manner until it reached the lowest point 35 mg/mL (*p* \< 0.05) ([Fig. 1A](#f1){ref-type="fig"}). In addition, Bel-7404 cells treated with 35 mg/mL laminarin exhibited significantly lower cell viability than those without treatment (0 mg/mL) at 24, 48, and 72 h post-treatment (*p* \< 0.05) ([Fig. 1B](#f1){ref-type="fig"}). The viability of Bel-7404 cells treated with 35 mg/mL laminarin for 48 h was only 46.20% of that of cells without treatment (0 mg/mL). Results consistent with Bel-7404 cells were also observed in HepG2 cells (*p* \< 0.05) ([Fig. 1C, D](#f1){ref-type="fig"}). The viability of HepG2 cells treated with 35 mg/mL laminarin for 48 h was only 42.85% of that of cells without treatment (0 mg/mL).

![The viability (OD at 450 nm) of Bel-7404 and HepG2 cells detected by WST-8 cell proliferation assay. **(A)** Bel-7404 cells treated with laminarin at different concentrations for 48 h. **(B)** Bel-7404 cells treated with 35 mg/mL laminarin for different times. **(C)** HepG2 cells treated with laminarin at different concentrations for 48 h. **(D)** HepG2 cells treated with 35 mg/mL laminarin for different times. \* and \*\*Represent significantly different at *p* \< 0.05 and *p* \< 0.01 when compared with 35 mg/mL laminarin, respectively.](cbr.2019.3179_figure1){#f1}

Laminarin promoted the apoptosis of HCC cells {#s013}
---------------------------------------------

The apoptosis of Bel-7404 and HepG2 cells was detected by flow cytometry. It showed that the Bel-7404 cells were mainly in the late phase of apoptosis and the HepG2 cells were mainly in the early phase of apoptosis ([Fig. 2A, B](#f2){ref-type="fig"}). The treatment with laminarin (48 h) significantly increased the apoptosis rate of Bel-7404 cells in a dose-dependent manner (*p* \< 0.05) ([Fig. 2C](#f2){ref-type="fig"}). The apoptosis rate of Bel-7404 cells treated with 35 mg/mL laminarin for 48 h was ∼2.72 times higher than the rate in those without treatment (0 mg/mL). Results consistent with Bel-7404 cells were also observed in HepG2 cells (*p* \< 0.05) ([Fig. 2D](#f2){ref-type="fig"}). The apoptosis rate of HepG2 cells treated with 35 mg/mL laminarin for 48 h was ∼8.18 times higher than that of those without treatment (0 mg/mL).

![The apoptosis of Bel-7404 and HepG2 cells detected by flow cytometry. **(A)** Flow cytometry graphs of Bel-7404 cells treated with laminarin at different concentrations for 48 h. **(B)** Flow cytometry graphs of HepG2 cells treated with laminarin at different concentrations for 48 h. **(C)** Apoptosis rate of Bel-7404 cells treated with laminarin at different concentrations for 48 h. **(D)** Apoptosis rate of HepG2 cells treated with laminarin at different concentrations for 48 h. The letters a, b, c, d, and e represent 0, 5, 15, 25, and 35 mg/mL laminarin, respectively.](cbr.2019.3179_figure2){#f2}

Laminarin promoted tumor growth in mice {#s014}
---------------------------------------

The antitumor effects of laminarin in HCC were further evaluated in Hepa 1--6 tumor-bearing mice. As shown in [Figure 3A](#f3){ref-type="fig"}, the tumor volume of mice injected with Hepa 1--6 cells significantly increased in a time-dependent manner (*p* \< 0.05). The treatment with laminarin significantly decreased the tumor volume in a dose-dependent manner beginning on the 10th day (*p* \< 0.05) ([Fig. 3A](#f3){ref-type="fig"}). After injection for 30 d, the tumor weights of mice were significantly decreased by laminarin treatment in a dose-dependent manner (*p* \< 0.05) ([Fig. 3B](#f3){ref-type="fig"}). The tumor growth inhibition rates of 400, 800, and 1200 mg/kg·d laminarin were 21.38%, 56.60%, and 67.92%, respectively ([Fig. 3C](#f3){ref-type="fig"}). In addition, after the injections were given for 30 d, body weight was significantly lower in mice injected with 1200 mg/kg·d laminarin than it was in mice injected with 0, 400, and 800 mg/kg·d laminarin (*p* \< 0.05). No significant differences in body weight were observed among mice injected with 0, 400, and 800 mg/kg·d laminarin ([Fig. 3D](#f3){ref-type="fig"}).

![The tumor growth in Hepa 1--6 tumor-bearing mice. **(A)** Tumor volume of mice injected with laminarin at different concentrations and time points. **(B)** Tumor weight of mice injected with laminarin at different concentrations for 30 d. **(C)** Inhibition rate of laminarin at different concentrations. **(D)** Body weight of mice injected with laminarin at different concentrations for 30 d. \*, \# and \^Represent significant differences with *p* \< 0.05 when compared with 0, 400, and 800 mg/kg·d laminarin, respectively.](cbr.2019.3179_figure3){#f3}

Laminarin upregulated SMP-30 in HCC cells {#s015}
-----------------------------------------

The expression of SMP-30, a senescence marker, was detected in HCC and normal liver cells. As shown in [Figure 4](#f4){ref-type="fig"}, the expression of SMP-30 was significantly lower in Bel-7404 and HepG2 cells than in LO2 cells at both the mRNA and protein levels (*p* \< 0.05). Notably, the expression of SMP-30 was significantly increased by the treatment with 35 mg/mL laminarin for 48 h in Bel-7404 and HepG2 cells at both the mRNA and protein levels (*p* \< 0.05). The expression of SMP-30 was not significantly influenced by laminarin treatment in LO2 cells ([Fig. 4](#f4){ref-type="fig"}). It showed that the effect of laminarin to upregulate SMP-30 in Bel-7404 cells is more obvious.

![The expression of senescence marker protein-30 (SMP-30) in LO2, Bel-7404, and HepG2 cells. **(A)** Relative expression of SMP-30 at the mRNA level. **(B)** Protein bands of SMP-30 and β-actin. **(C)** Relative expression of SMP-30 at the protein level. \*Represents a significant difference with *p* \< 0.05 when compared with LO2 cells; \# represents a significant difference with *p* \< 0.05 when compared with 0 h.](cbr.2019.3179_figure4){#f4}

Discussion {#s016}
==========

HCC is a common liver cancer that seriously affects the quality of life of patients.^[@B16]^ Since the toxicity of and tolerance to conventional antitumor drugs greatly limit the treatment outcomes of HCC, natural bioactive substances have become a substitute with great therapeutic potential.^[@B7]^ Until now, obvious antitumor effects in HCC have been identified in diverse natural bioactive substances, such as gambogic acid, tea catechins, genistein, berberine, resveratrol, curcumin, artemisinin, and matrine.^[@B17]^ In this study, the antitumor roles of laminarin, a polysaccharide in seaweed, were evaluated. We found that laminarin significantly inhibited the proliferation and promoted the apoptosis of Bel-7404 and HepG2 cells *in vitro*. Further, laminarin also significantly inhibited tumor growth in Hepa 1--6 tumor-bearing mice.

β-glucan is a group of β-D-glucose polysaccharides that exhibits obvious biological activity against chronic diseases, such as diabetes mellitus, improper digestion, and cancer. The antitumor roles of β-glucan have been identified by some studies. For example, β-glucan from Lentinus edodes inhibits tumor growth in mice by suppressing the proliferation and enhancing the apoptosis of MCF-7 breast cancer cells.^[@B18]^ (1 → 3)-β-D-glucan from *Saccharomyces cerevisiae* significantly decreases the volume and weight of S180 tumors in mice.^[@B19]^ β-glucan from the Maitake mushroom induces the apoptosis of prostate cancer PC-3 cells.^[@B20]^ Since laminarin is a 1,3- and 1,6-glycosidic bond-linked β-D-polysaccharide, we suspected that laminarin may also have antitumor potential in HCC. In this study, the specific roles of laminarin in the proliferation and apoptosis of HCC cells were evaluated. We found that 48 h of laminarin treatment significantly decreased the viability and increased the apoptosis rates of Bel-7404 and HepG2 cells in a dose-dependent manner. These findings illustrate that laminarin exerts antitumor effects similar to those of β-glucan. Moreover, it looks as though the effect of laminarin levels off at 35 mg/mL concentration. It shows that the cells have a certain threshold of sensitivity to polysaccharide drugs. When the dose exceeds this threshold, its effect does not change significantly. Of note, and different from the β-glucan or (1 → 3)-β-D-glucan, an even higher dose of laminarin (35 mg/mL) was used in our experiment. It appears that the number and structure of glycosidic bonds in polysaccharides will affect their function. The activity of glucans with 1,3- and 1,6- branches requires higher doses than that of glucans with 1,3- branch or no branch.

In addition, previous studies have proved that laminarin inhibits the colony formation of CC DLD-1 cells and promotes the apoptosis of CC HT-29 cells.^[@B10],[@B11]^ Consistent with its roles in CC cells, laminarin can also inhibit the proliferation and promote the apoptosis of HCC cells *in vitro*. To further identify the antitumor effects of laminarin in HCC *in vivo*, laminarin was injected into Hepa 1--6 tumor-bearing mice. We found that the injection of laminarin significantly decreased the tumor volume and tumor weight in a dose-dependent manner. These findings are consistent with a previous study on (1 → 3)-β-D-glucan mentioned earlier and further illustrate that laminarin can inhibit HCC tumor growth *in vivo*. However, excessive laminarin may also be harmful since the body weights of mice were significantly decreased by the injection with 1200 mg/kg·d laminarin.

The regulatory mechanisms of laminarin in tumors are complex and have been suggested to be associated with ErbB2 phosphorylation, mitochondria, and the death receptor pathway in CC cells.^[@B9],[@B10],[@B21]^ In this study, the expression of a prognostic marker of HCC, SMP-30, was detected. We found that the treatment with laminarin significantly increased the expression of SMP-30 in Bel-7404 and HepG2 cells but not in LO2 cells, compared with the expression in the control cells. These findings illustrate that laminarin specifically upregulates SMP-30 in HCC cells. Previous studies have proved that overexpression of SMP30 inhibits the proliferation of HepG2 cells and blocks cells in G1 and G2/M phase.^[@B15]^ Therefore, we suspect that laminarin may inhibit the proliferation and promote the apoptosis of HCC cells by upregulating SMP-30. In addition, the data showed that the effect of laminarin to upregulate SMP-30 in Bel-7404 cells is more obvious than that in HepG2 cells. Considering that the Bel-7404 cells were mainly in the late phase of apoptosis and the HepG2 cells were mainly in the early phase of apoptosis, we speculated that SMP-30 is mainly directed to the late apoptosis.

In conclusion, laminarin significantly inhibited proliferation and promoted apoptosis in Bel-7404 and HepG2 cells *in vitro*, and it significantly suppressed tumor growth in Hepa 1--6 tumor-bearing mice *in vivo*. The antitumor effects of laminarin in HCC were closely associated with the upregulation of SMP-30. Laminarin may be a promising therapeutic agent for HCC. However, the specific effects of laminarin on the invasion and migration of HCC cells, as well as the metastasis of tumors *in vivo*, are still unclear, and further studies are still needed.

Conclusions {#s017}
===========

Laminarin inhibited the proliferation of Bel-7404 and HepG2 cells and the growth of tumor in Hepa 1--6 tumor-bearing mice by upregulating SMP-30.
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